150 related articles for article (PubMed ID: 10887633)
21. Benefits of less frequent injections in advanced prostate cancer.
Ortiz M
Aust Fam Physician; 2015 Jun; 44(6):429-30. PubMed ID: 26209999
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.
Fowler JE; Gottesman JE; Reid CF; Andriole GL; Soloway MS
J Urol; 2000 Sep; 164(3 Pt 1):730-4. PubMed ID: 10953135
[TBL] [Abstract][Full Text] [Related]
23. Eligard. Tiny implant fights prostate cancer.
Nursing; 2002 May; 32(5):18. PubMed ID: 12035639
[No Abstract] [Full Text] [Related]
24. Systemic allergic dermatitis caused by the solvent of Eligard.
Ruiz-Hornillos J; Henríquez-Santana A; Moreno-Fernández A; González IG; Sánchez SR
Contact Dermatitis; 2009 Dec; 61(6):355-6. PubMed ID: 20059500
[No Abstract] [Full Text] [Related]
25. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer.
Fowler JE;
Urology; 2001 Sep; 58(3):430-4. PubMed ID: 11549494
[TBL] [Abstract][Full Text] [Related]
27. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.
Wright JC; Tao Leonard S; Stevenson CL; Beck JC; Chen G; Jao RM; Johnson PA; Leonard J; Skowronski RJ
J Control Release; 2001 Jul; 75(1-2):1-10. PubMed ID: 11451492
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
29. [Granulomas induced by injections of leuprorelin acetate (Enantone®)].
Bruneu-Avierinos Y; Monestier S; Tasei AM; Gaudy-Marqueste C; Grob JJ; Richard MA
Ann Dermatol Venereol; 2011 Jan; 138(1):35-7. PubMed ID: 21276459
[TBL] [Abstract][Full Text] [Related]
30. Eligard: leuprolide acetate in a novel sustained-release delivery system.
Sartor O
Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
[TBL] [Abstract][Full Text] [Related]
31. New drug delivery system may offer clinical advantages in prostate cancer treatment.
Oncology (Williston Park); 2000 Sep; 14(9):1291. PubMed ID: 11033825
[No Abstract] [Full Text] [Related]
32. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
33. Leuprorelin: a leading role in advanced prostate cancer therapy.
Persad R
Hosp Med; 2003 Jun; 64(6):360-3. PubMed ID: 12833832
[TBL] [Abstract][Full Text] [Related]
34. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment.
Herranz Amo F
Arch Esp Urol; 2010 May; 63(4):275-81. PubMed ID: 20508303
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndrome and prostate cancer.
Glode LM
Cancer; 2008 May; 112(10):2103-5. PubMed ID: 18404693
[No Abstract] [Full Text] [Related]
37. [Characteristics, effects, side effects of the LH-RH agonist].
Miyanaga N; Akaza H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
[No Abstract] [Full Text] [Related]
38. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
Morsi A; Jamal S; Silverberg JD
Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous granulomas caused by subcutaneous injections of leuprorelin acetate.
Kluger N; Hahtola S; Lempinen T; Jeskanen L
Presse Med; 2017 Oct; 46(10):966-968. PubMed ID: 28919272
[No Abstract] [Full Text] [Related]
40. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
Wieder JA; Soloway MS
J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
